IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,32 -0,71 (-0,86%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
59.054,96 +1.697,70 (+2,96%)
Adaptimmune Therapeutics plc (ADAP)
Después del cierre:
Adaptimmune Therapeutics plc
60 Jubilee Avenue
Milton Park
Abingdon OX14 4RX
United Kingdom
44 12 3543 0000
https://www.adaptimmune.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 449
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Adrian G. Rawcliffe | CEO, Principal Accounting Officer & Director | 1,06M | 199,16k | 1972 |
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Co-Founder & Chief Business & Strategy Officer | 677,4k | N/A | 1967 |
| Mr. Gavin Hilary James Wood ACA, BA (Hons) | Chief Financial Officer | 666,34k | N/A | 1970 |
| Mr. William C. Bertrand Jr., Esq., J.D. | Chief Operating Officer | 707,34k | 76,95k | 1965 |
| Dr. Elliot Norry B.A., M.D. | Chief Medical Officer | 676,19k | 65,02k | 1964 |
| Ms. Joanna Brewer Ph.D. | Chief Scientific Officer | N/A | N/A | 1976 |
| Dr. Juli P. Miller Ph.D. | VP of Corporate Affairs & Investor Relations | N/A | N/A | N/A |
| Ms. Kerry Sharp | Senior VP & General Council | N/A | N/A | N/A |
| Dana Lynch | Senior Director of Corporate Communications | N/A | N/A | N/A |
| Mr. John Lunger | Chief Patient Supply Officer | 645,91k | 148,2k | 1970 |
Descripción
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Gobierno corporativo
El ISS Governance QualityScore de Adaptimmune Therapeutics plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
